Bolt Biotherapeutics

BOLT

Market cap $7.36M

BOLT Hedge Fund Activity: Q1 2026 in Review

24 of the 8,130 institutional investors tracked by Wall St. Rank reported a position in Bolt Biotherapeutics (BOLT) for Q1 2026, worth a combined $2.49M — down 24% from $3.3M a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new BOLT positions and 2 closed out — a net gain of 4 holders — while 6 added to existing stakes and 3 trimmed.

The largest buyer was Lynx1 Capital Management, opening a new position worth an estimated $160K. The largest seller was Pivotal bioVenture Partners Investment Advisor, cutting an estimated $271K.

• 24 institutional investors held Bolt Biotherapeutics (BOLT) as of Q1 2026, up from 21 in Q4 2025.
• Funds reported $2.49M of Bolt Biotherapeutics stock for Q1 2026, down 24% quarter-over-quarter.
• 6 funds opened new Bolt Biotherapeutics positions in Q1 2026 and 2 closed out, a net change of +4 holders.
• The largest Bolt Biotherapeutics buyer in Q1 2026 was Lynx1 Capital Management, an estimated $160K added.
• The largest Bolt Biotherapeutics seller in Q1 2026 was Pivotal bioVenture Partners Investment Advisor, an estimated $271K sold.

Based on aggregated 13F filings for Q1 2026.